Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maximilian W. Schenk"'
Autor:
Maximilian W. Schenk, Sam Humphrey, A. S. Md Mukarram Hossain, Mitchell Revill, Sarah Pearsall, Alice Lallo, Stewart Brown, Samuel Bratt, Melanie Galvin, Tine Descamps, Cong Zhou, Simon P. Pearce, Lynsey Priest, Michelle Greenhalgh, Anshuman Chaturvedi, Alastair Kerr, Fiona Blackhall, Caroline Dive, Kristopher K. Frese
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
The emergence of acquired resistance to standard platinum-etoposide chemotherapy in small cell lung cancer (SCLC) is a common event. Here, the authors using paired pre-treatment and post-chemotherapy circulating tumour cell patient-derived explant (C
Externí odkaz:
https://doaj.org/article/a99beedee95f4504bd782063edbc7711
Publikováno v:
Lallo, A, Schenk, M, Frese, K, Blackhall, F & Dive, C 2017, ' Circulating tumor cells and CDX models as a tool for preclinical drug development ', Translational Lung Cancer Research, vol. 6, no. 4, pp. 397 . https://doi.org/10.21037/tlcr.2017.08.01
Lung cancers are the main cause of cancer-related deaths worldwide. Efforts placed to improve the survival of lung cancer patients and untangle the complexity of this disease, have resulted in the generation of hundreds of lung cancer cell lines and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358ab86e044d2acccc0e6946b5747242
https://doi.org/10.21037/tlcr.2017.08.01
https://doi.org/10.21037/tlcr.2017.08.01
Autor:
Kristopher K. Frese, Maximilian W Schenk, Therese Pham, Christina Kalderén, Alice Lallo, Sakshi Gulati, Fiona H Blackhall, Crispin J. Miller, Ioannis S. Pateras, Ulrika Warpman Berglund, Garima Khandelwal, Vassilis G. Gorgoulis, Christopher P. E. Chester, Caroline Dive, Thomas Helleday
Publikováno v:
British journal of pharmacology. 176(3)
Background and Purpose Small cell lung cancer (SCLC) is an aggressive disease with median survival of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a46bf2c1dd5155b854dc972ab710d348
https://pubmed.ncbi.nlm.nih.gov/30427531
https://pubmed.ncbi.nlm.nih.gov/30427531
Autor:
Fabio Gomes, Fiona H Blackhall, Kristopher K. Frese, Katie Baker, Martin Forster, Maximilian W Schenk, Alice Lallo, Victoria Foy, Caroline Dive
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Foy, V, Schenk, M, Baker, K, Gomes, F, Lallo, A, Frese, K, Forster, M, Dive, C & Blackhall, F 2017, ' Targeting DNA damage in SCLC ', Lung Cancer, vol. 114, 11, pp. 12-22 . https://doi.org/10.1016/j.lungcan.2017.10.006
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Foy, V, Schenk, M, Baker, K, Gomes, F, Lallo, A, Frese, K, Forster, M, Dive, C & Blackhall, F 2017, ' Targeting DNA damage in SCLC ', Lung Cancer, vol. 114, 11, pp. 12-22 . https://doi.org/10.1016/j.lungcan.2017.10.006
SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of clinical trials there has been no change to the stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d985075e4d708fa0a6f83fb0013005
https://hdl.handle.net/10400.17/2823
https://hdl.handle.net/10400.17/2823
Autor:
Christopher J. Morrow, A. Hughes, Kristopher K. Frese, Fiona H Blackhall, Cassandra L Hodgkinson, Garima Khandelwal, Sakshi Gulati, Robert Sloane, Melanie Galvin, Stewart Brown, Elaine Cadogan, Francesca Trapani, Nicole Simms, Kathryn Simpson, Lynsey Priest, Crispin J. Miller, Maximilian W Schenk, Alice Lallo, Mark J. O'Connor, Zhongwu Lai, Caroline Dive
Publikováno v:
Lallo, A, Frese, K K, Morrow, C, Szczepaniak Sloane, R, Gulati, S, Schenk, M W, Trapani, F, Simms, N, Galvin, M, Brown, S, Hodgkinson, C L, Priest, L, Hughes, A M, Lai, Z, Cadogan, E B, Khandelwal, G, Simpson, K L, Miller, C, Blackhall, F H, O'Connor, M J & Dive, C 2018, ' The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 24, no. 20, pp. 5153-5164 . https://doi.org/10.1158/1078-0432.CCR-17-2805
Purpose: Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer (SCLC), a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bd8b880ff2df8bc1fda1e24f565218d
https://pubmed.ncbi.nlm.nih.gov/29941481
https://pubmed.ncbi.nlm.nih.gov/29941481